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Abstract
Pancreatic cancer is a leading cause of cancer-related death worldwide, and its burden is 
destined to increase. Multimodal treatment is crucial to achieve a cure, but standardiza-
tion is far to come. Borderline resectable disease is the most challenging situation to face. 
An anatomically resectable disease may hide a biologically aggressive or undiagnosed 
systemic disease. Whether the patient has to undergo surgery first or after locoregional 
or systemic therapy is still unknown. Decision-making stands on low-quality evidences 
since RCTs are lacking. Neoadjuvant treatment may downstage the tumor and treat an 
early systemic disease, selecting patients for surgery in order to achieve a margin-free 
resection and avoid early recurrences and useless pancreatectomies. Resectable patients 
without other worrisome features may benefit from a surgery-first approach, while all 
other nonmetastatic patients should be enrolled in trials to rule out the outcomes of neo-
adjuvant treatments.
Keywords: pancreatic cancer, neoadjuvant treatment, pancreatic surgery, borderline 
resectable, locally advanced
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1. Introduction
By 2030 pancreatic cancer (PaC) is expected to be the second cancer-related cause of death [1]. 
Its 5-year survival in nonmetastatic stages currently ranges between 3 and 14% [2] regardless 
of treatment. Surgery remains the only chance for cure since the 5-year survival in T1 N0 
resected patients reaches 55.2% [3]; therefore, the standard of care advocates a surgery-first 
approach in case of resectable disease followed by adjuvant treatment (ADT), but neoadju-
vant approaches are spreading either in resectable or borderline resectable (BLR) and locally 
advanced (LA) patients. The National Comprehensive Cancer Network (NCCN) states that 
there is limited evidence to recommend specific neoadjuvant regimens off-study [4]. While 
the only choice in LA PaC is a locoregional chemoradiation (CRT) or systemic chemotherapy 
(CHT) and subsequent revaluation, for resectable and BLR, we must choose between a sur-
gery-first approach and a neoadjuvant treatment (NADT). Over 40% of patients who have 
clinically a resectable disease are found unresectable at surgery, even though this percentage 
drops to 20% if a diagnostic laparoscopy is added to the preoperative diagnostic panel [5]; 
one out of five patients are eventually misdiagnosed as resectable or BLR while having a 
LA disease. Even in a high-volume referral hospital, the percentage of successfully resected 
patients at surgical exploration is as low as 51% [6]. Results of first-line pancreatectomy may 
be very poor with only 20% of patients receiving radical surgery and 80% presenting tumor 
within 1 mm from margin or direct microscopic margin infiltration [7]. In a Korean series, 
9.1% of patients presenting with PaC diagnosis were clinically staged as BLR [8], about 27% 
of whom required a vascular resection (VR) in order to achieve their pancreatectomy [9], but 
histological invasion of resected vessels is confirmed only in 56.7% of specimens [10]. Finally, 
up to 28% of successfully resected patients will not undergo ADT because of surgical morbid-
ity, poor performance status, refusal, or early recurrence [10]. As Buchler said, unfortunately 
available evidences supporting NADT come from retrospective studies in which treatment 
protocols vary greatly and patient cohorts are often mixed with resectable, BLR, and LA [11].
Whereas features of a metastatic disease are evident, dealing with PaC and NADT, a foreword 
has to be spent to clarify the terminology “resectable,” “borderline resectable,” and “locally 
advanced.” To that end, we will first focus on the definition of borderline resectable disease 
and then analyze the outcomes of NADT from a surgical point of view.
2. Definition of borderline resectable pancreatic cancer
In origin the term “marginally resectable” pancreatic cancer was used for tumors without a 180° 
free fat plane around SMA, SMV, or PV for at least 1 cm [12]; this outlined a tumor with a high 
probability of positive-margin surgery. In the following years, several revisions took place, and the 
term “borderline resectable” was adopted, but still there is no universal consensus on its definition.
2.1. Anatomic criteria
The pancreatic glands lay in the deepest abdomen in direct contact with several major vascu-
lar structures. It is encased between the mesenteric root and the two main splanchnic arteries. 
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With the PV/SMV-SMA plane being its bed and the celiac trunk being its roof, resectability 
and thus possibility of cure are played in few millimeters. As shown in Figure 1, PaC may 
arise in the head, body, or tail of the pancreas; therefore, respectability definition differs along 
with its location whether on the right of the left border of PV/SMV (head) or on the left of 
the left aortic border (tail) or in between (body). In surgery few things are technically impos-
sible; this is heavily surgeon-dependent because it relies in its skills and will. That is why 
several institutions/associations have tried and classified PaC resectability depending on its 
involvement of nearby structures. In Table 1 the anatomic criteria for definitions of borderline 
resectable disease from the classifications of five major institutions are shown: MD Anderson 
Cancer Center [9], American Hepato-Biliary-Pancreatic Association/Society of Surgery of the 
Alimentary Tract/Society of Surgical Oncology (AHBPA/SSAT/SSO) [13], Alliance A021101 
[14], IAP [3], and NCCN [4]. Any situation with a more extensive vascular involvement will 
obviously be classified under the “locally advanced/unresectable” definition, whereas a less 
extensive one will define a resectable disease. Despite the effort to standardize definitions 
and make patients and features comparable among radiologist and surgeons, in some clas-
sifications, terms like “allowing for safe reconstruction” still appear increasing confusion 
among professionals and trials. It is interesting how some may consider a unique SMV/PV 
<180° involvement that implies a venous resection, as a resectable disease, whereas an arte-
rial involvement is always considered at least borderline resectable; this is due to the surgical 
Figure 1. Schematic representation of pancreatic vascular relationships. AA, Aorta; IVC, inferior vena cava; PHA, 
proper hepatic artery; PV, portal vein; SMV, superior mesenteric vein; SMA, superior mesenteric artery; IMV, inferior 
mesenteric vein; SV, splenic vein; SA, splenic artery; LGA, left gastric artery; CA, celiac axis; CHA, common hepatic 
artery; GDA, gastro-duodenal artery.
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International consensus IAP [3] BR-PV (SMV/PV involvement alone):
• SMV/PV: tumor contact 180° or greater or bilateral narrowing/occlusion, not 
exceeding the inferior border of the duodenum.
• SMA, CA, CHA: no tumor contact/invasion.
BR-A (arterial involvement):
• SMA, CA: tumor contact of less than 180° without showing deformity/stenosis;
• CHA: tumor contact without showing tumor contact of the PHA and/or CA.
NCCN Guidelines [4] VENOUS
• Solid tumor contact with the SMV or PV of >180°, contact of ≤180° with contour 
irregularity of the vein or thrombosis of the vein but allowing for resection and 
reconstruction
• Solid tumor contact with the inferior vena cava (IVC).
ARTERIAL
If head/uncinate process:
• Solid tumor contact with CHA without extension to CA or hepatic artery bifurca-
tion allowing for resection and reconstruction.
• Solid tumor contact with the SMA of ≤180°
• Solid tumor contact with variant arterial anatomy
If body/tail:
• Solid tumor contact with the CA of ≤180°
• Solid tumor contact with the CA of >180° without involvement of the AA and 
with intact and uninvolved GDA thereby permitting a modified Appleby 
procedure.
Intergroup criteria Alliance 
A021101 [14]
• a TVI with SMV or PV ≥180° of the circumference of either vein’s wall or short-
segment occlusion of either vein amenable to reconstruction;
• any TVI with CHA amenable to reconstruction;
• a TVI with SMA <180° of the circumference of the vessel wall.
AHBPA/SSO/SSAT consensus 
statement [13]
• Venous involvement of the SMV/PV demonstrating tumor abutment with or 
without impingement and narrowing of the lumen, encasement of the SMV/PV 
but without encasement of the nearby arteries, or short segment venous occlusion 
resulting from either tumor thrombus or encasement but allowing for resection 
and reconstruction.
• GDA encasement up to the CHA with either short segment encasement or direct 
abutment of the CHA, without extension to the CA.
• Tumor abutment of the SMA not to exceed >180° of the circumference of the 
vessel wall.
MD Anderson Cancer Center [9] • Tumor abutment (<180° of the circumference of the vessel) of the SMA or CA;
• Tumor abutment or encasement (>180° of the circumference of the vessel) of a 
short segment of the CHA;
• Short-segment occlusion of the SMV, PV, or SMV-PV confluence amenable to 
vascular resection and reconstruction.
BR, borderline resectable; PV, portal vein; SMV, superior mesenteric vein; SMA, superior mesenteric artery; CA, celiac 
artery; CHA, common hepatic artery; PHA, proper hepatic artery; AA, aorta; GDA, gastroduodenal artery; IVC, inferior 
vena cava; TVI, tumor-vessel interface.
Table 1. Anatomic criteria for borderline resectable disease.
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implications of venous and arterial resections, as the former does not increase either postop-
erative morbidity or mortality [15].
2.2. Biologic criteria
Besides anatomical features, PaC may have an intrinsic undiagnosed risk of early recurrent 
or micrometastatic disease linked to its biology; indeed, early recurrence occurs in 25% of 
resected patients [16], thus making surgery ineffective. Herein, some examples of biomark-
ers are predicting more aggressive disease. Preoperative CA19.9 > 300 U/ml and tumor size 
>3 cm [16], preoperative CEA >3 ng/ml and CA19.9 > 75 U/ml, N+ disease, and T3–T4 [17] 
are independent negative prognostic factors. Moreover, patients presenting with local dis-
ease have a 22% of SMAD-4 loss versus 78% of patients with metastatic disease [18]. In an 
era of tailored treatments, it should be reminded that every patient and every disease have 
their own characteristics that have to be taken into account in the therapeutic decision-mak-
ing. Lately, circulating tumor cells have been investigated as prognostic biomarkers, three 
or more CTCs/4 ml were an independent prognostic factor for the overall survival, and it 
accurately predicted occult metastatic disease [19]. That is why during the 20th meeting of 
the International Association of Pancreatology held in Sendai in 2016 a consensus of border-
line resectable definition has been drawn up that includes biological and conditional criteria. 
Biological criteria are a CA19.9 above 500 IU/ml and regional lymph node metastasis proven 
by biopsy or PET-CT. Conditional host-related criteria depends on the patient’s performance 
status defined by a PS score of 2 or more [3]. Thus, patients satisfying at least either an ana-
tomic, biologic, or conditional criteria are classified as borderline resectable.
3. Neoadjuvant treatment
3.1. Indications
A preoperative treatment has several theoretical advantages. First of all it delivers systemic 
therapy to all patients: at least 30% of patients do not receive adjuvant therapy after resec-
tion for a variety of reasons [20]. Then, it is shed in a highly perfused tumor bed that allows 
an in vivo testing of the tumor sensibility to the chemotherapeutic agent. Moreover, NADT 
should increase the probability of negative margin surgery (R0) and decrease the likelihood 
of nodal involvement and vascular resection (VR). Finally, it identifies tumors with an aggres-
sive biology and picks out patients who would not benefit from surgery because of early 
progression, recurrence, or previously undiagnosed metastatic disease. Whether those pre-
sumed advantages translate into real world is still under investigation. The role of NADT for 
PaC, especially for primary resectable ones, still remains controversial among other reasons 
because a quote of those patients undergoing neoadjuvant treatment will experience severe 
side effects and complications [21]. A comprehensive meta-analysis provides marginal sup-
port to the assumed benefit of contemplating neoadjuvant therapies for patients whose tumor 
was judged resectable at preoperative staging [22]. Neoadjuvant treatment should always be 
offered to BLR and LA diseases; nevertheless, since preoperative staging in PaC is far from 
being accurate, with 22.5% of patients brought to the operating room with curative intent 
found to be metastatic [6], it is crucial to treat every patient within registered trials.
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3.2. Outcomes
3.2.1. Toxicity
Unfortunately, every neoadjuvant regimen brings its own risk of toxicity, and a successful 
resection is more likely in case of completion of NADT [23]. A serious side effect might indefi-
nitely postpone surgery; that is why resectable patients are exposed to a shift from being a 
surgical patient to never being proposed for cure. This has to be taken into account while pro-
posing such treatment in selected patients. As shown in Table 2, it is reported that 29.4–36% of 
patients will experience grade 3 or 4 adverse effects during preoperative treatment [22, 24, 25], 
with 6% of patients giving up treatment because of its toxicity [26]. But up to 91% of patients 
initiated to NADT achieve the intended preoperative protocol [24].
3.2.2. Pathologic response
As seen in Table 3, up to 11.3% of BLR or LA PaC presented a complete pathologic response 
(ypT0) after NADT [27]. In this paper 83% of patients with ypT0 were dead or relapsed at a 
Author, year Article type Grade 3/4 toxicity
Dhir, 2017 [24] Metanalysis 36%
Marthey, 2015 [26] Cohort study 26%
Andriulli, 2012 [22] Metanalysis 31%
Gillen, 2010* [25] Metanalysis 29,4%
Kapoor, 2014 [37] Prospective 0%
*PaC AND periampullary tumors.
Table 2. Major toxicity.
Author, year Article type Complete 
pathological 
response
Partial pathological 
response
Stable 
disease
Progression
Dhir, 2017 [24] Metanalysis n.a. 20% 59% 16%
Hashemi-Sadraei, 
2017 [27]
Retrospective 11.3% (of resected 
patients)
n.a. n.a. n.a.
Marthey, 2015 [26] Cohort study 5.2% 28% 56% 16%
Addeo, 2015 [40] Retrospective 8.8% n.a. n.a. n.a.
Andriulli, 2012 [22] Metanalysis n.a. 22%* 50% 25%
Gillen, 2010† [25] Metanalysis 3.9% 29.1% 43.9% 20.8%
Heinrich, 2008 [38] Phase II trial 0% n.a. n.a. n.a.
Kim, 2017 [8] Retrospective 0% 65% 35% 0%
*Including complete path. resp.
†Pancreatic cancers AND periampullary tumors.
Table 3. Pathological response.
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median follow-up of 21.3 months [27], suggesting a systemic undiagnosed or uncontrolled 
disease. A 2010 meta-analysis shows 3.9% of complete pathologic response, 29.1% partial 
response, 43.9% stable disease, and 20.8% of progression during NADT [25]. A more recent 
2017 meta-analysis confirms those data with partial response or stable disease in 79% of treated 
patients (20 and 59%, respectively) while in progression in 16% of cases [24]. According to 
Gillen and coll. Pooled percentages of pathologic response did not vary much in the two 
groups of initially deemed resectable and non-resectable tumor patients [25]; this may be due 
to the fact that resectability is defined only by anatomical features, while probably a biological 
understanding of the disease would enhance clinical staging. Anyhow unfortunately, there 
are 16–32% of patients that will have to stop treatment because of progression [22, 26].
4. Surgery
Surgery is ideally recommended 4 to 8 weeks after neoadjuvant treatment [4] although it 
has been postulated that patients with a longer (>10 weeks) interval between RT and CHT 
and surgery could be more likely to have an improved pathological response, R0 resection, 
and OS [28]. According to a consensus statement drafted in 1999 [29], “standard” pancre-
atoduodenectomy includes regional lymphadenectomy around the duodenum and pancreas; 
“radical” pancreatoduodenectomy includes regional lymphadenectomy plus skeletonization 
of the proper hepatic artery (PHA), common hepatic artery (CHA), superior mesenteric artery 
(SMA) between the aorta (AA) and inferior pancreaticoduodenal artery, and the CA; dissec-
tion of the anterolateral aspect of the aorta and inferior vena cava (IVC) includes Gerota’s 
fascia; and lastly “extended radical” pancreatoduodenectomy includes “radical” pancreato-
duodenectomy and clearance of the anterior AA between the diaphragmatic hiatus (around 
the CA) and the origin of the common iliac arteries. Currently, extended lymphadenectomy is 
no more recommended as it increases costs [30], blood loss, and operative time without adding 
survival or staging advantages [31]. For what concerns vascular involvement, venous resec-
tion doesn’t affect preoperative mortality even if it may slightly increase morbidity; instead, 
arterial resection is still under major debate since it seems to have acceptable outcomes only 
in single high-volume centers’ reports [32]. In a French experience, patients that received a 
venous resection but whose tumor did not infiltrate the vessel at final histology, lived lon-
ger either than patients whose tumor eventually infiltrate the vein either than patients who 
did not require a vascular resection (42 months vs. 24 vs 22 respectively p = .04) [33]. This 
may even justify extreme positions such as calling upon routine VR during pancreatecto-
mies. According to the latest staging system of the American Joint Committee on Cancer (8th 
edition), venous infiltration doesn’t modify T stage: indeed T1 to 3 stages relies on tumor’s 
dimension and T4 is defined only in case of arterial involvement [34]; therefore, venous resec-
tion should not hold back surgeons from performing a pancreatectomy with curative intent.
4.1. Resectability
In a 2010 meta-analysis, surgical exploration after NADT was attempted in 69.5% of patients, 
but only 50.7% of NADT patients were eventually successfully resected (that is 77.9% of 
explored patients) [25]. In a more recent meta-analysis, the rate of resected patients raised to 
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65%, but reported percentages vary from 26.7% to 89.28% depending on variability of protocols 
and patients [35]. In fact resection was more likely in resectable patients (73.6%) than in non-
resectable ones (33.2%) [25]. In John Hopkins Hospital’s experience, recently published, resec-
tion in BLR patients after neoadjuvant treatment was achieved in 44% of cases [36], while it was 
possible only in 26.7% of LA patients in an Indian report [37] versus 89.28% of pancreatecto-
mies in resectable patients of a Swiss trial [38]. Those are single experiences that cannot reflect 
general reality, and the few existing neoadjuvant RCTs report a protocol achievement range 
of 18.18–70% [39]. Anyway, after neoadjuvant treatment between 26.5% [8] and 97.7% [40] of 
patients successfully receiving a pancreatectomy will require a VR. Table 4 reports resection’s 
outcomes of selected experiences and meta-analysis.
4.2. Morbidity and mortality
According to the recently reported experience of an Italian group with more than 150 pancre-
atectomies per year, NADT exposes patients to a reduced incidence of postoperative fistula 
and hemorrhage; unfortunately, in spite of this, the average clinical burden is increased [41]. 
Back in 2010 a morbidity of 34.2% with a mortality of 5.3% in eventually resected patients was 
reported as a meta-analytical data after NADT [25]. Some claimed perioperative mortality 
to be much higher (6.7–7%) after NADT with FOLFIRINOX [26, 40, 42] compared to upfront 
Author, year Article type ITT 
population
Explored/ITT Resected/ITT Vascular resection/
resected
Epelboym, 
2014 [42]
Retrospective Mixed ITT=explored 82.2% 64.3%
Gillen, 2010* 
[25]
Metanalysis Mixed 69.5% 50.7% n.a.
Sherestha, 
2017 [36]
Retrospective BLR 54.9% 44% n.a.
Kim, 2017 [8] Retrospective BLR ITT = explored 85% 26.5%
D’Angelo, 
2017 [35]
Metanalysis Mixed n.a. 65% n.a.
Addeo, 2015 
[40]
Retrospective Mixed ITT=explored 77.5% 97.7%
Marthey, 2015 
[26]
Cohort study LA n.a. 66% n.a.
Kapoor, 2014 
[37]
Prospective LA n.a. 26.7% n.a.
Andriulli, 2012 
[22]
Metanalysis Mixed 66% 74% (of 
explored)
n.a.
Heinrich, 2008 
[38]
Phase II trial Resectable 93% 89.28% 12.5%
ITT, intention to treat; PaC, pancreatic cancer; BLR, borderline resectable; LA, locally advanced.
*PaC AND periampullary tumors.
Table 4. Resectability.
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resected patients regardless of VR, while others reported mortality in PV/SMV resection to 
be as low as 3% [33]. In literature a great amount of data make it muddler to understand the 
picture of the actual situation.
4.3. Resection margins
The goal of multimodal treatment is to achieve a margin-free surgery, taking into account that 
additional resection to achieve negative neck margin after R1 frozen section is not associated to 
improve survival [43]. In pancreatectomies’ specimens the most frequently involved margin is the 
retroperitoneal one (39%) [6]; that is why VR assumes a central role in academic discussions. In 
fact among patients requiring VR NADT reduced significantly R1 rate (from 34.9 to 19.6%) [40]. 
After NADT, intention-to-treat (ITT) R0 rates have been reported to be 23–63% depending on 
their preoperative assessed resectability [24]. In resected patients R0 rate was estimated by a meta-
analysis to be as high as 94%; that is to say that this data comes from nonrandomized trials [35]. 
Indeed, clear resection margins were present in 40% and 75% of cases in Landry [44] and Palmer’s 
[45] RCTs. Lastly, pathologists have to be aware that after a preoperative treatment what seems to 
be a tumor-free margin could be only the expression of a reduction of density of tumor cells [46].
5. Role of adjuvant treatment
In several trials a significant benefit of ADT after pancreatectomy has been demonstrated [39], 
but whether additional adjuvant treatment is necessary in preoperatively treated patients is 
not clear as it may not provide additional survival benefit [40, 47]. In a Korean series 5.9% of 
patients undergone NADT and pancreatectomy recurred before having the chance to begin 
ADT [8]. In a Japanese experience, NADT was found to be a negative factor in predicting 
failure to achieve ADT therapy along with preoperative prognostic nutritional index, intra-
operative blood transfusion, organ/space surgical site infections, and advanced UICC stage; 
however, this association was not confirmed at multivariate analysis, and only poor prognos-
tic nutritional index, intraoperative blood transfusions, and organ/space surgical site infec-
tions were confirmed to be significantly associated with ADT dropout [48]. What is the real 
weight of NADT in precluding the administration of ADT? An American group reported the 
administration of ADT to 90% of resected patients after a long-term NADT regimen [23]; thus, 
all that matters is probably only a correct patient selection.
6. Survival
Survival goes hand in hand with successful surgical resection with a wide clear (R0) margin 
(>1 mm) giving the chance for an OS of 35 months, while R0 < 1 mm of 16 months involved 
margin (R1) resections of 14 months and unresected patients only 11 months (p < .001) [6]. Even 
in case of complete pathologic response (ypT0) after NADT and pancreatectomy cure is not 
guaranteed; indeed, in a series of ypT0 patients, 83.3% were dead or relapsed after a median of 
21.3 months [27]. In NADT patients, resection hangs the scales in survival: in a meta-analysis 
OS in eventually resected patients was 22.78 months versus 9.89 in non-resected patients with 
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an ITT OS of 16.7 months (please see Table 5) [36]. Such results are in line with a high-volume 
center such as Johns Hopkins Hospital, in which after NADT median overall survival (mOS) of 
resected patients was 25.8 months versus 11.9 months in eventually non-resected patients [36]. 
Results in the setting of RCTs aren’t equally encouraging with ITT OS ranging 9.9–19.4 months 
in NADT setting versus 12.5–29.8 months in ADT one [39], but it shouldn’t be forgotten that 
in the former we are dealing with resectable patients, while in the latter with resected ones; 
therefore, we could make a comparison only including in the latter group also patients who 
undergone explorative laparotomies. In a retrospective series, thanks to less lymphovascular 
invasion, less perineural invasion, and lower T and N stages, NADT-treated and NADT-resected 
patients presented a better median overall survival than primarily resected ones (27.3 months 
vs. 19.7 months, p < .05) [42]. In their experience, concerning vascular resections, there was no 
difference among NADT patients between VR+ and VR- in terms of OS [42].
7. Discussion
Every surgery resident is raised with two warnings:
“Eat when you can, sleep when you can, and don’t mess with the pancreas.”
and
“God put the pancreas in the retroperitoneum so the surgeon won’t mess with it.”
Perioperative mortality in pancreatectomies has been as high as 15% in the 1950s–1970s and 
since then has dropped to 1.5% in selected centers [49]. Nevertheless, pancreatic surgery for PaC 
has still high in-hospital mortality rates, as highlighted by an analysis of the German national 
database; it ranges from 12.2% in very-low-volume hospitals (with a median of four resections 
per year) to 7.1% in high-volume ones (with a median of 105 resections per year) [50]. Surgery 
is the only chance for cure of patients affected by PaC—and besides it decreases costs compared 
to palliative treatments [51]—but multimodal treatment is crucial for long-term survival [52]. 
Therefore, patients’ selection has to be accurate since in one hand patients sent to NADT may 
miss the window for resection and in the other surgical complications may indefinitely postpone 
systemic treatment. Currently, there are no reliable clinical predictors of resectability [36]: 
in order not to lose the chance for resection, all patients receiving NADT should be surgi-
cally explored unless evident metastatic disease as fibrosis and inflammation can mimic a LA 
 unresectable  disease. As Buanes said, “one of the major problems worldwide is the underutiliza-
tion of surgery in resectable pancreatic cancer” [53], and, especially after NADT, clinical staging 
Author, year Type of article ITT-OS (months)
Andriulli, 2012 [22] Metanalysis 16.4
D’Angelo, 2017 [35] Metanalysis 16.7
Sherestha, 2017 [36] Retrospective 15.1
ITT-OS, intention-to-treat overall survival.
Table 5. Survival.
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is unreliable. Indeed, there may be relevant tumor regression during NADT around involved 
vessels despite the absence of radiographic signs of tumor downstaging [54]. Not even PET-CT 
has shown to be reliable in differentiating benign from malignant disease after NADT [55].
In Miura’ study, while in the ITT analysis, clinically BLR disease was an independent poor 
prognostic indicator, among resected patients OS did not differ between preoperatively 
classified resectable and BLR patients [56]. Similarly, OS of previously resected patients 
(20.87 months) was not better than the overall resected ones (22.78 months) in a recent meta-
analysis [35]; this reflects the inadequacy of current preoperative staging and confirms that 
once resected, preoperative staging doesn’t influence patients’ outcomes. Once more, our 
efforts have to be straight at bringing patients to a curative surgery.
Supporters claim NADT to increase patients’ selection, but unfortunately despite NADT, 
there is still a proportion of patients early progressing after surgery [8], for those patients 
we need more accurate staging and prognostic biomarkers in order to avoid useless surgery.
Overall, only 57.7% of PaC patients will receive the intended ADT—of which 24.1% more 
than 70 days after surgery—and this is mainly due to surgical complications: a wound dehis-
cence may seem trivial, but it lowers the percentage of patients receiving systemic therapy 
to 43.6% versus 61.8% in patients without any postoperative morbidity [57]. NADT bypasses 
this dropout administrating treatment before surgery; the price to pay is that about one-third 
of patients experiencing major toxicity and about one-fifth progressing, but in resected ones, 
surgery seems not to be affected by the worst outcomes.
That NADT is safe and helpful in upfront technically unresectable patients and is self-evident, 
which other choices would they have? But how can we know if it is advisable in resectable 
patients regardless to vascular (whether venous or arterial) or en bloc multi-organ resections? 
A German group tried to design an RCT comparing NADT versus upfront surgery, in both 
cases followed by ADT, to rule out the question. Unfortunately, even if a slight increase in 
OS, R0, and N0 rates was seen in NADT arm, the trial had to be stopped due to slow recruit-
ing; thus, sample size was not reached and results were not significant [58]. According to 
Mellon and colleagues, patients with BLR or LA PaC and sufficient response to neoadjuvant 
multi-agent chemotherapy and stereotactic body radiation therapy have similar or improved 
perioperative and long-term survival outcomes compared to upfront resected patients [59].
The problem dealing with NADT is that RCTs are lacking; the existing three trials conducted 
on resectable PaC report a protocol achievement of 18.18–70% and an ITT survival of 9.9–
19.4 months [39]. Selected retrospective single-institution experiences over resectable BLR and 
LA PaC report OS up to 43.4 months in resected patients following chemotherapy or chemo-
radiation [60]. In a paper comparing NADT in BLR-LA to upfront resected patients, the ITT 
analysis showed worse survival for the former (17.0 vs. 22.1 mo, p = 0.029); such comparison 
has little significance because in the first group 61.6% of patients was eventually unresectable, 
while the upfront surgery group accounted only resected and adjuvant-treated patients [59]. 
Indeed, there was no significant difference and even a slight trend favoring NADT, in survival 
between the two groups among only resected patients (33.5 vs. 23.1 mo, p = 0.057) [59].
Histological confirmation of the disease is mandatory before administering NADT even 
though up to 16% of preoperatively cyto−/histologically diagnosed PaC eventually receive a 
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final pathological diagnosis other than PaC [38], thus receiving a useless neoadjuvant treat-
ment. In Golcher’s study pathological diagnosis of PaC at biopsy has been rejected in 4.5% 
of resected patients (because of the finding of a distal choledochal adenocarcinoma and a 
duodenal adenocarcinoma) [58].
8. Conclusions
The use of different resectability classifications, different NADT protocols, and selective 
reporting in the past years makes the comparison of literature extremely tricky. Outcomes 
tend to be better outside an RCT context; literature is influencing our conduct, but strong 
evidences come only from well-designed randomized trials. The unanimous adoption of the 
International Association of Pancreatology’s classification [3] and standardized protocols and 
trials might clarify the impact of neoadjuvant treatments on the survival of those patients.
Assuming that patients are unresectable at diagnosis in the vast majority of cases; that even 
if they are suitable for NADT, more than 20% give up because of progression or toxicity; that 
barely an half is then resected; that, of those, up to 20% have positive margins; and that nor a 
negative resection margin nor a complete pathologic response shelters the patient from recur-
rence, we may say that nowadays PaC treatment desperately needs un upgrading.
Waiting for strong evidences, a reasonable behavior could be to resect all patients primarily 
resectable without any biologic worrisome feature (high CA19.9, high CEA, tumor >3 cm, 
positive nodes) and to offer all nonmetastatic patients neoadjuvant treatment in order to 
select those eligible for surgical exploration. Obviously, this has always to be done in the 
context of randomized controlled trials.
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